GMZ2 Vaccine-Induced Antibody Responses, Naturally Acquired Immunity and the Incidence of Malaria in Burkinabe Children.
GLURP-R2
GMZ2
MSP3-K1
Plasmodium falciparum
malaria vaccine
naturally acquired immunity
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
03
2022
accepted:
22
04
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
22
6
2022
Statut:
epublish
Résumé
GMZ2 is a malaria vaccine candidate evaluated in a phase 2b multi-centre trial. Here we assessed antibody responses and the association of naturally acquired immunity with incidence of malaria in one of the trial sites, Banfora in Burkina Faso. The analysis included 453 (GMZ2 = 230, rabies = 223) children aged 12-60 months old. Children were followed-up for clinical malaria episodes for 12 months after final vaccine administration. Antibody levels against GMZ2 and eleven non-GMZ2 antigens were measured on days 0 and 84 (one month after final vaccine dose). Vaccine efficacy (VE) differed by age group (interaction, (12-35 months compared to 36-60 months), p = 0.0615). During the twelve months of follow-up, VE was 1% (95% confidence interval [CI] -17%, 17%) and 23% ([CI] 3%, 40%) in the 12 - 35 and 36 - 60 months old children, respectively. In the GMZ2 group, day 84 anti-GMZ2 IgG levels were associated with reduced incidence of febrile malaria during the follow up periods of 1-6 months (hazard ratio (HR) = 0.87, 95%CI = (0.77, 0.98)) and 7-12 months (HR = 0.84, 95%CI = (0.71, 0.98)) in the 36-60 months old but not in 12-35 months old children. Multivariate analysis involving day 84 IgG levels to eleven non-vaccine antigens, identified MSP3-K1 and GLURP-R2 to be associated with reduced incidence of malaria during the 12 months of follow up. The inclusion of these antigens might improve GMZ2 vaccine efficacy.
Identifiants
pubmed: 35720297
doi: 10.3389/fimmu.2022.899223
pmc: PMC9200992
doi:
Substances chimiques
Antigens, Protozoan
0
GMZ2 vaccine
0
Immunoglobulin G
0
Malaria Vaccines
0
Banques de données
PACTR
['ATMR2010060002033537']
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
899223Informations de copyright
Copyright © 2022 Dassah, Adu, Tiendrebeogo, Singh, Arthur, Sirima and Theisen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Vaccine. 2004 Mar 12;22(9-10):1188-98
pubmed: 15003647
N Engl J Med. 2015 Nov 19;373(21):2025-2037
pubmed: 26488565
Vaccine. 2009 Jan 1;27(1):62-71
pubmed: 18977268
J Infect Dis. 2007 Jan 15;195(2):279-87
pubmed: 17191173
Mol Biochem Parasitol. 2000 Nov;111(1):123-30
pubmed: 11087922
Am J Trop Med Hyg. 1991 Sep;45(3):297-308
pubmed: 1928564
Commun Biol. 2021 Aug 19;4(1):984
pubmed: 34413459
J Infect Dis. 2013 Aug 1;208(3):479-88
pubmed: 23624363
Clin Diagn Lab Immunol. 2005 Feb;12(2):242-8
pubmed: 15699417
Nat Rev Immunol. 2015 Jun;15(6):335-49
pubmed: 25976513
Malar J. 2016 Feb 27;15:123
pubmed: 26921176
Infect Immun. 2004 Oct;72(10):5630-7
pubmed: 15385460
J Infect Dis. 2018 Aug 14;218(6):956-965
pubmed: 29733355
Infect Immun. 2020 Mar 23;88(4):
pubmed: 31964745
N Engl J Med. 2011 Sep 15;365(11):1004-13
pubmed: 21916638
PLoS One. 2009;4(3):e4708
pubmed: 19262754
N Engl J Med. 2009 Jul 30;361(5):468-77
pubmed: 19641203
Vaccine. 2013 Aug 20;31(37):3936-42
pubmed: 23800539
Vaccine. 2009 May 18;27(23):3090-8
pubmed: 19428923
PLoS One. 2011;6(7):e22525
pubmed: 21829466
Parasitol Today. 1997 Sep;13(9):353-7
pubmed: 15275050
J Infect Dis. 2000 Mar;181(3):1202-5
pubmed: 10720556
J Infect Dis. 2017 Feb 15;215(4):623-630
pubmed: 28329101
Sci Adv. 2019 Sep 25;5(9):eaax4489
pubmed: 31579826
Infect Immun. 1998 Jan;66(1):11-7
pubmed: 9423833
Trends Parasitol. 2010 Jul;26(7):363-9
pubmed: 20466591
Vaccine. 2009 Nov 16;27(49):6862-8
pubmed: 19755144
Vaccine. 2010 Sep 24;28(41):6698-703
pubmed: 20696154
J Infect Dis. 2019 Jun 19;220(2):275-284
pubmed: 30820557
J Infect Dis. 2013 Feb 1;207(3):511-9
pubmed: 23204168
Parasitology. 2009 Oct;136(12):1445-56
pubmed: 19627632
Infect Immun. 2008 May;76(5):2240-8
pubmed: 18316390
BMC Med. 2014 Jul 01;12:108
pubmed: 24980799
PLoS Med. 2007 Nov 13;4(11):e320
pubmed: 18001147
BMC Res Notes. 2017 Sep 8;10(1):472
pubmed: 28886727
JCI Insight. 2017 Jan 12;2(1):e89154
pubmed: 28097230
Infect Immun. 2000 May;68(5):2617-20
pubmed: 10768952
Open Forum Infect Dis. 2015 Apr 10;2(2):ofv044
pubmed: 26380342
Microb Cell Fact. 2018 Apr 5;17(1):55
pubmed: 29618355
Malar J. 2008 Jul 29;7:142
pubmed: 18664257
Mol Biochem Parasitol. 1997 Aug;87(2):231-4
pubmed: 9247935
Vaccine. 2011 Apr 12;29(17):3284-92
pubmed: 21349366
Clin Diagn Lab Immunol. 1995 Jan;2(1):30-4
pubmed: 7719909
PLoS One. 2012;7(12):e51692
pubmed: 23300556
Infect Immun. 2001 May;69(5):3286-94
pubmed: 11292751
Parasite Immunol. 2007 Aug;29(8):387-94
pubmed: 17650180
Nature. 1961 Nov 25;192:733-7
pubmed: 13880318
Expert Rev Vaccines. 2017 Sep;16(9):907-917
pubmed: 28699823
PLoS One. 2012;7(9):e46188
pubmed: 23029433
PLoS One. 2019 Jun 27;14(6):e0217903
pubmed: 31246965
Parasite Immunol. 2004 Jun-Jul;26(6-7):265-72
pubmed: 15541030
Scand J Immunol. 2004 Apr;59(4):363-72
pubmed: 15049780
J Infect Dis. 2002 Mar 15;185(6):820-7
pubmed: 11920300
Blood. 1994 Sep 1;84(5):1594-602
pubmed: 8068948
J Infect Dis. 2007 Nov 1;196(9):1304-12
pubmed: 17922394
PLoS One. 2011;6(12):e28165
pubmed: 22145028
Vaccine. 2016 Aug 31;34(38):4536-4542
pubmed: 27477844
Infect Immun. 2004 Jan;72(1):247-52
pubmed: 14688102